Answers are grounded in this paper and cite their sources.
Machine learning models increasingly contribute to drug discovery, but their utility depends on performing reliably in their intended deployment setting. Although model generalization is invoked frequently, the drug discovery community lacks a shared vocabulary for how models actually achieve transferability beyond their training data. We argue that achieving generalization requires examining how a model’s inductive bias interacts with its training data to shape the notion of similarity it learns. Without a bias that makes relevant recurring relationships easier to learn as opposed to incidental correlations, models exploit dataset-specific shortcuts. These shortcuts yield high benchmark performance but fail in prospective applications. We therefore propose evaluation principles tailored to a model’s architecture, using diagnostic controls and train−test splits that distinguish transferable learning from the retrieval of familiar training data. This Perspective shows how representational choices shape failure modes across pose-dependent, pose-independent, and foundation model paradigms, and provides a practical framework to help researchers expose shortcuts and interpret predictions.
No takes yet. Share an insight, caveat, or question.
Benjamin P. Brown (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: